Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT05131438 | An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL) | no longer available | — | — | EQRx International, Inc.INDUSTRY | 1 | Mar 27, 2023 |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05692050 | Expanded Access to Epcoritamab | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 3, 2023 | clinicaltrials |
| NCT04825652 | 177Lu-PSMA-617 Managed Access Program for mCRPC Patients | no longer available | — | — | Advanced Accelerator ApplicationsINDUSTRY | 0 | Jan 13, 2023 | clinicaltrials |
| NCT02960620 | Therasphere for Unresectable Primary or Secondary Liver Neoplasia | no longer available | — | — | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2022 | clinicaltrials |
| NCT00419367 | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2022 | clinicaltrials |
| NCT04559555 | MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 9, 2022 | clinicaltrials |
| NCT04599647 | EAP for the Treatment of Glioblastoma With PVSRIPO | no longer available | — | — | Istari Oncology, Inc.INDUSTRY | 1 | Jun 29, 2022 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT05392374 | Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT03123211 | Expanded Access to Veliparib | no longer available | — | — | AbbVieINDUSTRY | 0 | May 24, 2022 | clinicaltrials |
| NCT04289155 | Individual Patient Compassionate Use of GX-I7 | no longer available | — | — | Genexine, Inc.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT03134131 | Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas | no longer available | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT03501940 | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | no longer available | — | — | Andrei IagaruOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03594162 | Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03914885 | Compassionate Use Re-Infusion of ATLCAR.CD30 | no longer available | — | — | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT03126617 | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 0 | Nov 29, 2021 | clinicaltrials |
| NCT04453397 | Expanded Access for TNB-383B in a Subject With Relapsed/Refractory Multiple Myeloma | no longer available | — | — | TeneoOne Inc.INDUSTRY | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02985658 | Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer | no longer available | — | — | University of WashingtonOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT02475382 | Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen(CheckMate 169) | no longer available | — | — | Bristol-Myers SquibbINDUSTRY | 2 | Nov 27, 2020 | clinicaltrials |
| NCT01947608 | Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 10 | Nov 3, 2020 | clinicaltrials |
| NCT01196208 | A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 | no longer available | — | — | Seagen Inc.INDUSTRY | 15 | Sep 21, 2020 | clinicaltrials |
| NCT04137822 | Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer | no longer available | — | — | Impatients N.V. trading as myTomorrowsINDUSTRY | 2 | Aug 14, 2020 | clinicaltrials |
| NCT02174679 | 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) | no longer available | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02568943 | An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 6 | Apr 8, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT03460782 | An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas | no longer available | — | — | Center Trials & TreatmentOTHER | 8 | Nov 8, 2019 | clinicaltrials |
| NCT02297529 | Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma | no longer available | — | — | AmgenINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT02715843 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | no longer available | — | — | Molecular Templates, Inc.INDUSTRY | 1 | Oct 11, 2019 | clinicaltrials |
| NCT03503890 | Expanded Access to Rovalpituzumab Tesirine | no longer available | — | — | AbbVieINDUSTRY | 0 | Sep 10, 2019 | clinicaltrials |
| NCT03492489 | Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma | no longer available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Aug 1, 2019 | clinicaltrials |
| NCT03123952 | Expanded Access to ABT-414 | no longer available | — | — | AbbVieINDUSTRY | 0 | Jul 15, 2019 | clinicaltrials |
| NCT03850704 | Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma | no longer available | — | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 22, 2019 | clinicaltrials |
| NCT02955446 | Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies | no longer available | — | — | University of Colorado, DenverOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03723096 | Expanded Access for CC-4047 | no longer available | — | — | CelgeneINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT02547675 | Rociletinib (CO-1686) USA Expanded Access Program | no longer available | — | — | Clovis Oncology, Inc.INDUSTRY | 1 | Sep 25, 2018 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT02784158 | An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer | no longer available | — | — | Ariad PharmaceuticalsINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT02083484 | Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | no longer available | — | — | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2018 | clinicaltrials |
| NCT03311542 | Expanded Access for Pembrolizumab (MK-3475) | no longer available | — | — | Center Trials & TreatmentOTHER | 4 | Jan 10, 2018 | clinicaltrials |
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut(CDX-110) | no longer available | — | — | Celldex TherapeuticsINDUSTRY | 0 | Oct 18, 2017 | clinicaltrials |
| NCT03085186 | Treatment With Crizotinib Single Patient Expanded Access IND 134375 | no longer available | — | — | Jean M. Tersak, M.D.OTHER | 0 | Aug 29, 2017 | clinicaltrials |
| NCT02666209 | Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | no longer available | — | — | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2017 | clinicaltrials |
| NCT00701168 | Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer | no longer available | — | — | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 23, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Apr 28, 2023source: clinicaltrials